A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer
Akin Atmaca(Heidelberg University), E. Jaeger(Krankenhaus Nordwest), Antje Neumann(Krankenhaus Nordwest), Martin Göttlicher, Alexander Maurer, Emily C. Martin(St. Michael's Hospital), Alexander Knuth(National Center for Cancer Care and Research), Ingrid Bartsch(Krankenhaus Nordwest), S. Al-Batran(Krankenhaus Nordwest), Thorsten Heinzel(Friedrich Schiller University Jena)
Cited by 10
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
|Advances in cancer research|2006|455
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
|Proceedings of the National Academy of Sciences|2000|427